

JAN 30 2009

510(K) SUMMARYNovel Spinal System**Submitter:**

Medyssey Co., Ltd.

Jang, Jong Wuk

4F, Science Tower, 722-3, Jihaeng-dong

Dongducheon-city, Gyeonggi-do, Korea

Phone : 82-31-879-0415

Fax : 82-31-879-0414

Contact:

KoDent Inc.

Jung Bae Bang

13340 E. Firestone Blvd. Suite J

Santa Fe Springs, CA 90670

Phone : 562-404-8466

Fax : 562-404-2757

Date Prepared: April 18, 2008**Device Class:** Class II

Classification Name: Spinal Interlaminar
Fixation Orthosis(KWP)
Per 21 CFR 888.3050

Spinal Pedicle Screw
Fixation Orthosis(MNI)
Per 21 CFR 888.3070

Spondylolisthesis Spinal
Fixation Orthosis(MNH)
Per 21 CFR 888.3070

Classification Panel: Orthopedics**Product Code:** KWP, MNI, MNH**Device Name:** Novel Spinal System

- Device Description:** Novel Spinal System, internal fixation device for spinal surgery comprise rods, pedicle screws, cross link as well as set screw. Various forms and sizes of these implants are available, so that adaptations can always be made to take into account the pathology and individual patient.
- Intended Use:** The Novel Spinal System is a non-cervical spinal fixation device intended for posterior, non-pedicle fixation for the following indications: degenerative disc disease (DDD) (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies); spondylolisthesis; trauma (i.e. fracture or dislocation); spinal stenosis; curvatures (i.e. scoliosis, kyphosis; and/or lordosis); tumor; pseudoarthrosis; and failed previous fusion. The Novel Spinal System is also intended for non-cervical pedicle screw fixation for the following indications: trauma (i.e. fracture or dislocation); spinal stenosis; curvatures (i.e. scoliosis, kyphosis; and/or lordosis); tumor; pseudoarthrosis; and failed previous fusion. It is also indicated for the treatment of severe spondylolisthesis (grades 3 and 4) of the L5-S1 vertebra in skeletally mature patients receiving fusion by autogenous bone graft having implants attached to the lumbar and sacral spine (L3 to sacrum) with removal of the implants after the attainment of a solid fusion.
- Materials:** The devices are manufactured from Ti6Al-4V ELI alloy per ASTM and ISO Standards.
- Performance Data:** Performance data per ASTM F1717 were submitted to characterize the subject Novel Spinal System components addressed in this notification.

Predicate Devices

The subject device is substantially equivalent to the following predicate devices:

* *ISOLA Spine System (DePuy Spine, Inc; K070300)*

* *Denali Spinal System (K2M, LLC; K042635)*

Comparison to Predicate Devices

Testing and other comparisons have established that the subject of Novel Spinal System is substantially equivalent in design, materials, indications and intended use, packaging, labeling, and performance to other predicate devices of the type currently marketed in the U.S.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Medyssey, Co., Ltd
% Kodent Inc.
Jung Bae Bang
13340 E. Firestone Boulevard, Suite J
Santa Fe Spring, California 90670

JAN 30 2009

Re: K081153

Trade/Device Name: Novel Spinal System
Regulation Number: 21 CFR 888.3070
Regulation Name: Pedicle screw spinal system
Regulatory Class: II
Product Code: MNI, MNH
Dated: January 26, 2009
Received: January 26, 2009

Dear Jung Bae Bang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indication for Use**510(K) Number (if known):** _____**Device Name:** Novel Spinal System**Indication for Use:**

The Novel Spinal System is a pedicle screw system indicated for the treatment of severe Spondylolisthesis (Grade 3 and 4) of the L5-S1 vertebra in skeletally mature patients receiving fusion by autogenous bone graft having implants attached to the lumbar and sacral spine (L3 to sacrum) with removal of the implants after the attainment of a solid fusion.

In addition, the Novel Spinal System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic lumbar and sacral spine: degenerative Spondylolisthesis with objective evidence of neurological impairment, fracture, dislocation, scoliosis, kyphosis, spinal tumor and failed previous fusion (pseudarthrosis).

Prescription Use X

AND/OR

Over-The-Counter _____

(Part 21 CFR 801 Subpart D)

(Per 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)**Division of General, Restorative,
and Neurological Devices****510(k) Number** K081153